Sökning: onr:"swepub:oai:DiVA.org:umu-176044" >
Targeted therapy fo...
-
Hofmann, FabianUmeå universitet,Urologi och andrologi
(författare)
Targeted therapy for metastatic renal cell carcinoma
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
John Wiley & Sons,2020
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-176044
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-176044URI
-
https://doi.org/10.1002/14651858.CD012796.pub2DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:for swepub-publicationtype
Anmärkningar
-
Related publication: Hofmann F., Marconi L.S.O., Stewart F., Lam T.B.L., Bex A., Canfield S.E., Ljungberg B. Targeted therapy for metastatic renal cell carcinoma [Protocol - Intervention]. Cochrane Database of Systematic Reviews 2017, (9): CD012796. DOI:10.1002/14651858.CD012796
-
Background: Several comparative randomised controlled trials (RCTs) have been performed including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors since the publication of a Cochrane Review on targeted therapy for metastatic renal cell carcinoma (mRCC) in 2008. This review represents an update of that original review.Objectives: To assess the effects of targeted therapies for clear cell mRCC in patients naïve to systemic therapy.Search methods: We performed a comprehensive search with no restrictions on language or publication status. The date of the latest search was 18 June 2020.Selection criteria: We included randomised controlled trials, recruiting patients with clear cell mRCC naïve to previous systemic treatment. The index intervention was any TKI‐based targeted therapy.Data collection and analysis: Two review authors independently assessed the included studies and extracted data for the primary outcomes: progression‐free survival (PFS), overall survival (OS) and serious adverse events (SAEs); and the secondary outcomes: health‐related quality of life (QoL), response rate and minor adverse events (AEs). We performed statistical analyses using a random‐effects model and rated the certainty of evidence according to the GRADE approach.Main results: We included 18 RCTs reporting on 11,590 participants randomised across 18 comparisons. This abstract focuses on the primary outcomes of select comparisons.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Chang Hwang, E.
(författare)
-
Lam, Thomas B.L.
(författare)
-
Bex, Axel
(författare)
-
Yuan, Yuhong
(författare)
-
Marconi, Lorenzo S.O.
(författare)
-
Ljungberg, Börje,Professor,1949-Umeå universitet,Urologi och andrologi(Swepub:umu)bolj0001
(författare)
-
Umeå universitetUrologi och andrologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cochrane Database of Systematic Reviews: John Wiley & Sons:101469-493X
Internetlänk
Hitta via bibliotek
Till lärosätets databas